Financials
Financial year 2025
Optimapharm from Hamme (Vl.), company number BE0635584382, closed financial year 2025 with a result of € 92,091 after tax. For that financial year Optimapharm recorded a gross margin of € 386,186 and equity of € 96,701. Compared with financial year 2024, the result moved from € 10,759 to € 92,091. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.
€ 96,701
▲ € 92,091 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 92,091
▲ € 81,331 vs 2024
Profit after tax over the fiscal year.
€ 40,320
▲ 155% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 78,101.
People and assets in 2025
1
Average over the fiscal year, from the social balance sheet.
€ 257,158
▲ 11% vs 2024
€ 257,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 6,371
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 16,524
▲ € 14,871 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 88,692
▲ 84% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 34,618 | € 214,017 | € 247,337 | € 386,186 | ▲ 56% |
| Profit after taxes | € 2,639 | € 25,262 | € 10,759 | € 92,091 | ▲ € 81,331 |
| Equity | € -31,411 | € -6,149 | € 4,610 | € 96,701 | ▲ € 92,091 |
| Total debts | € 178,403 | € 98,491 | € 97,335 | € 152,601 | ▲ 57% |
| Cash | € 16,409 | € 26,206 | € 15,806 | € 40,320 | ▲ 155% |
| Retained profit | € -50,011 | € -24,749 | € -13,990 | € 78,101 | ▲ € 92,091 |
| Balance sheet total | € 146,991 | € 92,342 | € 101,946 | € 249,302 | ▲ 145% |
| Employees (FTE) | 0.2 | 0.8 | 1 | 1 |
Key figures of Optimapharm, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Optimapharm?
What happened at Optimapharm in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 92,091 (▲ € 81,331 vs 2024). Source: NBB ↗
- Mirna SENJUG NOVAK became a director. NBB
- Ivana WALLER became a director. NBB
- New establishment in Hamme (Vl.). KBO
- Start of the company according to the CBE. KBO
In short
From € 2,639 profit in 2022 to € 92,091 profit in 2025.
Paid € 38,761 in corporate taxes since 2022.
Best year ever: 2025, with € 92,091 profit.
On average € 386,200 of value added per employee in 2025.
A new publication or filing at Optimapharm? We notify you, reason included.
Follow OptimapharmDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Optimapharm are Mirna SENJUG NOVAK and Ivana WALLER.
Directors
According to the 2025 annual accounts
Mirna SENJUG NOVAK
Bestuurder
since 2023
Ivana WALLER
Bestuurder
since 2023
Establishments
Establishment units
Physical locations of this company
Zwaarveld 41D
9220 Hamme (Vl.)
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0635.584.382
- VAT number
- BE 0635.584.382
- Registered office
- Zwaarveld 41D, 9220 Hamme (Vl.)
- Names & denominations
- Optimapharm
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 August 2015
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Overige zakelijke dienstverlening, neg
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria
Administratieve en ondersteunende activiteiten ten behoeve van kantoren
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
+3